25C-NBOH

Co-administration of 25C-NBOH with other QT-prolonging drugs (antiarrhythmics, certain antibiotics, antipsychotics, methadone) creates additive risk of fatal cardiac arrhythmia through combined QT interval extension.

Documented cardiomyocyte toxicity and electrophysiological disruption in animal models indicate direct cardiac stress. Structural heart disease eliminates the physiological reserve needed to tolerate these effects.

25C-NBOH significantly increased QT and RR intervals in rat ECG studies and decreased cardiomyocyte viability in vitro. Pre-existing cardiac arrhythmias create unacceptable additive risk of fatal dysrhythmia.

Individuals with congenital long QT syndrome are at extreme risk of fatal torsades de pointes arrhythmia when exposed to any QT-prolonging substance. 25C-NBOH has documented QT-prolonging effects in animal models.

Multiple NBOMe case series document seizures as a serious adverse effect at supratherapeutic doses. The shared pharmacological mechanism (potent 5-HT2A agonism) and microgram dosing with steep dose-response curves make seizure risk applicable to 25C-NBOH. Pre-existing seizure disorders lower the threshold for this adverse effect.

Serotonergic psychedelics as a class carry risk of precipitating psychotic episodes in predisposed individuals. The high potency and full 5-HT2A agonist efficacy of 25C-NBOH may amplify this risk relative to partial agonists.

25C-NBOH is expected to be primarily metabolized by CYP2D6 (by analogy with 25I-NBOH). Hepatic impairment could reduce clearance and increase systemic exposure. The availability of direct glucuronidation as an alternative pathway may partially mitigate this risk.

No reproductive or developmental toxicity data exist for 25C-NBOH or any NBOH-class compound. Standard precautionary absolute contraindication applies to all potent psychoactive substances without established pregnancy safety profiles.

Concurrent MAOI use with a potent 5-HT2A full agonist creates conditions for catastrophic serotonin accumulation. Serotonin syndrome can progress to hyperthermia, muscle rigidity, and multiorgan failure. This is a pharmacologically certain interaction independent of substance-specific data.

SSRIs and SNRIs increase serotonin syndrome risk when combined with 5-HT2A agonists. Additionally, some SSRIs (fluoxetine, paroxetine) are potent CYP2D6 inhibitors, which could reduce 25C-NBOH clearance and increase plasma levels — creating a dual pharmacokinetic and pharmacodynamic interaction.